secwatch.observer — SEC 8-K summary
======================================

Issuer:     DarioHealth Corp. (DRIO)
CIK:        0001533998
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-109166
Event type: debt
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DarioHealth amends credit facility; resets covenants, waives Q2/Q3 tests, adds $10M liquidity covenant
--------------------------------------------------------------------------------

- Credit agreement amended with Callodine Commercial Finance on Nov 5, 2025.
- Financial covenant testing waived for Q2 and Q3 2025; minimum unencumbered liquid assets set at $10M.
- Additional $2.5M funding from lenders now uncommitted and discretionary; exit fee increased by $150k.
- Warrant exercise price reduced from $16.556 to $15.3495; conversion price on up to $2.5M loan reduced to $15.3495.
- Amendment fee of $150k paid; 13-week cash-flow reporting required when liquidity below $11M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533998/000110465925109166/0001104659-25-109166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533998/000110465925109166/tm2530754d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer